Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$60.15 - $84.52 $120,179 - $168,870
-1,998 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$75.08 - $121.99 $15,091 - $24,519
-201 Reduced 9.14%
1,998 $214,000
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $5,692 - $9,532
-49 Reduced 2.18%
2,199 $288,000
Q2 2021

Aug 16, 2021

SELL
$130.4 - $225.58 $3,912 - $6,767
-30 Reduced 1.32%
2,248 $498,000
Q4 2020

Feb 16, 2021

BUY
$112.16 - $174.14 $242,938 - $377,187
2,166 Added 1933.93%
2,278 $394,000
Q3 2020

Aug 05, 2021

SELL
$58.05 - $111.31 $121,208 - $232,415
-2,088 Reduced 94.91%
112 $12,000
Q3 2020

Nov 16, 2020

BUY
$58.05 - $111.31 $127,710 - $244,882
2,200 New
2,200 $245,000
Q2 2020

Aug 12, 2020

SELL
$57.2 - $74.41 $18,361 - $23,885
-321 Closed
0 $0
Q1 2020

Aug 05, 2021

SELL
$57.05 - $95.75 $2.16 Million - $3.63 Million
-37,895 Reduced 99.16%
321 $22,000
Q1 2020

May 12, 2020

BUY
$57.05 - $95.75 $2.17 Million - $3.65 Million
38,113 Added 37002.91%
38,216 $2.57 Million
Q4 2019

Aug 05, 2021

SELL
$68.3 - $93.8 $546,741 - $750,869
-8,005 Reduced 98.73%
103 $9,000
Q4 2019

Feb 11, 2020

BUY
$68.3 - $93.8 $547,492 - $751,900
8,016 Added 8713.04%
8,108 $683,000
Q3 2019

Aug 05, 2021

SELL
$61.86 - $97.8 $515,664 - $815,260
-8,336 Reduced 98.91%
92 $7,000
Q3 2019

Nov 13, 2019

SELL
$61.86 - $97.8 $4.13 Million - $6.54 Million
-66,835 Reduced 88.8%
8,428 $630,000
Q2 2019

Aug 08, 2019

BUY
$42.22 - $63.23 $2.87 Million - $4.29 Million
67,873 Added 918.44%
75,263 $0
Q1 2019

May 15, 2019

SELL
$31.96 - $56.12 $1,278 - $2,244
-40 Reduced 0.54%
7,390 $0
Q3 2018

Nov 07, 2018

BUY
$32.0 - $52.4 $26,880 - $44,016
840 Added 12.75%
7,430 $0
Q2 2018

Aug 13, 2018

BUY
$19.85 - $32.0 $130,811 - $210,880
6,590 New
6,590 $0

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.07B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.